{
  "docId": "019de075-d6ea-7495-b63c-e64074d45b72",
  "docSlug": "3f99bbe59467be363a98d21e99cb078a",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 58,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The slide uses a visual comparison to highlight the safety advantage of NXC-201, specifically focusing on neurotoxicity and CRS duration.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/6",
  "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72",
  "deckJsonHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72.json",
  "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.4,
        "y": 0.27
      },
      "kind": "callout",
      "text": "NXC-201 Zero/low neurotoxicity vs. ~20-30% for others",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "143f5419-2c3d-4318-8f8d-8a0e8c457405",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.58,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Neurotoxicity (%) comparison",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "125d90c7-4856-445a-a2a9-1a5bd3814a20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.95,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Carvykti and Abecma FDA labels, Arcellx Corporate Presentation. Assayag, N., et al. European Society for Blood and Marrow Transplantation 49th Annual Meeting. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1088cb86-3338-49ee-b2a8-b28be449440c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.85,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "table",
      "text": "Comparison table of CRS metrics",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c691c11-4235-4bc8-98e7-ac249b6dae27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Is Overcoming Prolonged CRS and Neurotoxicity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b2fe2e1-10f7-4e49-9a4f-46d48937947b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "846f54f4-f7a6-4383-84ee-c6ee7dadd9a1",
      "evidence": "Direct comparison of NXC-201 against three competitors across multiple safety metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 27,
      "from": 4,
      "beatId": "e890a8f4-ce5b-494a-9258-fdd0f87cc84b",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Interest",
      "beatSlug": "aida-interest",
      "evidence": "The deck presents the problem, solution, competitive analysis, and traction",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}